Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 131
Selected: 0
NCT IDTitle
NCT00572572Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT03840967A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
NCT00860158Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
NCT00417248Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT01186458Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT02500121Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
NCT03783936Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
NCT01681433OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT04895046Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
NCT00234494Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT04289779Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT00532441Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
NCT06855225A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
NCT02982720Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
NCT04849364Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
NCT02499952Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03041181Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT04541173Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT00319735Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
NCT00216164Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02375672Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT03035630Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT06493019Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT05467891Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT01736917Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT00216060Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT06794229Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
NCT00526799Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
NCT04690855A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT02581059Efficacy of Ginseng for Patients on Regorafenib
NCT07218666Zanzalintinib in Men With Aggressive Variant Prostate Cancer
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT00613626Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT02549209Pembro/Carbo/Taxol in Endometrial Cancer
NCT02382406Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04848337Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT00632541A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
NCT02643043UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
NCT02343952Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
NCT05852717Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT03528408Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
NCT00472589A Biological Sample Collection Protocol of Women With and Without Breast Cancer
NCT04610684Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
NCT05442216Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents